Table 1.
β5 mutations found in cells with acquired resistance to bortezomib
| Cell lines | β5 | Fold difference (cell viability) | Ref. | |
| THP-1 | Ala49Thr | ~45-129 | Oerlemans et al.[30] | |
| Jurkat | Ala49Thr | Selected at 500 nM | Lu et al.[31] | |
| Jurkat |
Ala49Thr
Ala49Val Ala49Thr & Ala50Val |
~22 ~39 ~67 |
Lü et al.[70] | |
| HT-29 | Cys63Phe | ~30 | Suzuki et al.[7] | |
| CEM |
Cys52Phe
Ala49Val & Cys52Phe Ala49Thr |
~170 | Franke et al.[33] | |
| RPMI 8266 | Ala49Thr | ~40 | ||
| THP-1 | Ala49Thr | Selected at 100 nM | ||
| Ala49Thr & Met45Ile | Selected at 500 nM | |||
| Met45Ile | Selected at 100 nM (2nd independent panel) | |||
| Yeast |
Met45Ile
Cys63Phe |
21.4 0.8 |
Huber et al.[41] | |
| KBM7 | Met45Ile | Exposed to 18 nM bortezomib and 700 nM MG132 | Tsvetkov et al.[42] | |
| RPMI 6226 KMS11R FR4R XG-1R |
Met104Val | At least 5-fold | Shi et al.[35] | |
| MM1.SR | Thr80Ala | |||
| KMS-18 | Thr21Ala | ~2 | Allmeroth et al.[34] | |
| KMS-27 | Ala49Val | |||
| L363 MM.1S |
Ala50Val | 9 | Against ixazomib | Brünnert et al.[36] |
| Thr21Ala | 13 | |||
| Primary MM* |
Ala20Thr
Ala27Pro Met45Ile Cys63Tyr |
From an MM patient refractory to bortezomib | Barrio et al.[40] | |
| Tyr42Cys | One out of 1,241 newly diagnosed patients with MM | |||
*Detected after initiation of PAD (bortezomib, A and Dex)-pomalidomide treatment at TP3. MM: Multiple myeloma.